Should rivaroxaban (Xarelto) be held for low-to-moderate bleeding risk dental procedures such as resin‑composite restoration, crown placement, or bridge placement under local anesthesia in a patient with atrial fibrillation?

Should Rivaroxaban (Xarelto) Be Held for Low-to-Moderate Bleeding Risk Dental Procedures in AFib Patients?

For low-to-moderate bleeding risk dental procedures such as resin-composite restoration, crown placement, or bridge placement under local anesthesia, rivaroxaban should be held for 1 day (skip one dose) before the procedure, regardless of whether the patient takes it once or twice daily. 1

Evidence-Based Recommendation

The 2022 American College of Chest Physicians (ACCP) guideline provides the most authoritative and recent guidance on this question. The guideline explicitly states that rivaroxaban should be interrupted 1 day before low-to-moderate-bleed-risk procedures 1. This applies to all patients on rivaroxaban for atrial fibrillation, regardless of dose regimen.

Practical Implementation

Timing of interruption:

• If rivaroxaban is taken once daily in the morning: Skip the morning dose on the day before the procedure
• If rivaroxaban is taken once daily in the evening: Skip the dose two evenings before the procedure (to achieve the same 24-hour window)
• The procedure should be scheduled when drug levels are at their lowest (trough)

Resumption of therapy:

• Resume rivaroxaban at least 6 hours after the procedure if hemostasis is adequate 2
• If there is ongoing bleeding or surgical contraindication, delay resumption and consider temporary thromboprophylaxis

Why This Approach Is Safe

The French GIHP guidelines 2 corroborate this strategy, emphasizing that for low hemorrhagic risk procedures (which includes your listed dental procedures), a single day interruption is sufficient. The rapid offset of rivaroxaban (half-life 5-9 hours in healthy patients) means that 24 hours provides adequate clearance for procedures where hemostasis can be readily achieved.

Critical point: No bridging anticoagulation is needed. Both the ACCP 1 and French guidelines 2 explicitly state that heparin bridging increases bleeding risk threefold without reducing thrombotic events. The rapid onset/offset of DOACs makes bridging unnecessary and harmful.

Local Hemostatic Measures Are Essential

Even with appropriate interruption, local hemostatic measures should be employed:

• Primary closure with sutures
• Tranexamic acid-soaked gauze (5% solution) for 30-60 minutes 3
• Absorbable hemostatic agents if needed
• Minimize tissue trauma during the procedure

Research evidence supports this approach: A study of dental implant surgery in rivaroxaban patients showed no significant difference in bleeding complications when local hemostatic measures were used, even without interruption 3. However, another study found an 11.5% bleeding rate with continued rivaroxaban versus 0.7% in controls 4, reinforcing that the 1-day interruption recommended by guidelines provides an optimal balance.

Important Caveats

Renal function does NOT modify the interruption time for rivaroxaban in low-to-moderate risk procedures—1 day off is sufficient even with impaired renal function 1. This differs from dabigatran, which requires longer interruption with renal impairment.

Do not hold rivaroxaban longer than necessary. Extending the interruption beyond 1 day for these low-risk procedures unnecessarily increases stroke risk without additional bleeding benefit.

Patient-specific factors to verify:

• Confirm the patient's actual rivaroxaban dose and timing
• Check recent renal function (though it doesn't change the 1-day rule for low-risk procedures)
• Ensure no concomitant antiplatelet therapy that might increase bleeding risk
• Verify the procedure truly qualifies as low-to-moderate risk (no extensive soft tissue manipulation, no bone surgery beyond minimal alveolar work)

What Constitutes Low-to-Moderate Risk

Your listed procedures—resin-composite restoration, crown placement, and bridge placement under local anesthesia—clearly fall into the low-to-moderate bleeding risk category. These involve minimal to no soft tissue manipulation and no significant bone work. They are fundamentally different from extractions, implant placement, or periodontal surgery, which carry higher bleeding potential.